EE200100324A - Meetod aktiivse lümfotoksiin-beeta retseptori immunoglobuliinsete kimäärsete valkude kõrgtasemel ekspressiooniks ja puhastamiseks - Google Patents

Meetod aktiivse lümfotoksiin-beeta retseptori immunoglobuliinsete kimäärsete valkude kõrgtasemel ekspressiooniks ja puhastamiseks

Info

Publication number
EE200100324A
EE200100324A EEP200100324A EEP200100324A EE200100324A EE 200100324 A EE200100324 A EE 200100324A EE P200100324 A EEP200100324 A EE P200100324A EE P200100324 A EEP200100324 A EE P200100324A EE 200100324 A EE200100324 A EE 200100324A
Authority
EE
Estonia
Prior art keywords
purification
level expression
chimeric proteins
beta receptor
lymphotoxin beta
Prior art date
Application number
EEP200100324A
Other languages
English (en)
Estonian (et)
Inventor
L. Browning Jeffrey
Miatkowski Konrad
Meier Werner
Original Assignee
Biogen, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22345666&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EE200100324(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Biogen, Inc. filed Critical Biogen, Inc.
Publication of EE200100324A publication Critical patent/EE200100324A/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7151—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for tumor necrosis factor [TNF], for lymphotoxin [LT]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/02—Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biotechnology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cell Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Biomedical Technology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Compounds Of Unknown Constitution (AREA)
EEP200100324A 1998-12-17 1999-12-16 Meetod aktiivse lümfotoksiin-beeta retseptori immunoglobuliinsete kimäärsete valkude kõrgtasemel ekspressiooniks ja puhastamiseks EE200100324A (et)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US11275298P 1998-12-17 1998-12-17
PCT/US1999/029873 WO2000036092A2 (en) 1998-12-17 1999-12-16 METHOD FOR THE HIGH LEVEL EXPRESSION OF ACTIVE LYMPHOTOXIN-β RECEPTOR IMMUNOGLOBULIN CHIMERIC PROTEINS AND THEIR PURIFICATION

Publications (1)

Publication Number Publication Date
EE200100324A true EE200100324A (et) 2002-10-15

Family

ID=22345666

Family Applications (1)

Application Number Title Priority Date Filing Date
EEP200100324A EE200100324A (et) 1998-12-17 1999-12-16 Meetod aktiivse lümfotoksiin-beeta retseptori immunoglobuliinsete kimäärsete valkude kõrgtasemel ekspressiooniks ja puhastamiseks

Country Status (27)

Country Link
US (3) US7585946B2 (de)
EP (3) EP3006563A1 (de)
JP (4) JP4878676B2 (de)
KR (3) KR20020013482A (de)
CN (2) CN101289512A (de)
AT (1) ATE536372T1 (de)
AU (2) AU777232B2 (de)
BR (1) BR9916325B1 (de)
CA (1) CA2354539A1 (de)
CY (1) CY1117003T1 (de)
CZ (1) CZ20012156A3 (de)
DK (2) DK1141248T3 (de)
EA (1) EA005270B1 (de)
EE (1) EE200100324A (de)
ES (1) ES2554482T5 (de)
HK (1) HK1223398A1 (de)
HU (1) HUP0200064A2 (de)
IL (3) IL143670A0 (de)
IS (1) IS5959A (de)
NO (1) NO20012991L (de)
NZ (3) NZ538599A (de)
PT (1) PT2374872E (de)
SG (1) SG123531A1 (de)
SI (1) SI2374872T2 (de)
SK (1) SK8552001A3 (de)
TR (2) TR200504220T2 (de)
WO (1) WO2000036092A2 (de)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5925351A (en) * 1995-07-21 1999-07-20 Biogen, Inc. Soluble lymphotoxin-β receptors and anti-lymphotoxin receptor and ligand antibodies as therapeutic agents for the treatment of immunological disease
US7060667B1 (en) 1998-01-30 2006-06-13 Biogen Idec Ma, Inc. Treatment of follicular lymphomas using inhibitors of the LT pathway
TR200100974T2 (tr) * 1998-10-09 2001-11-21 Biogen, Inc. Virütik kaynaklı sistematik şok ve solunum zorluğunun,lenfotoksin beta yolunu bloke etmek suretiyle geri çevrilmesi
US20020168367A1 (en) * 2000-04-28 2002-11-14 Planet Biotechnology Incorporated Novel immunoadhesins for treating and preventing viral and bacterial diseases
US7951378B2 (en) 2000-04-28 2011-05-31 Planet Biotechnology Inc. Immunoadhesin comprising a chimeric ICAM-1 molecule produced in a plant
ATE325865T1 (de) * 2001-01-16 2006-06-15 Regeneron Pharma Isolierung von sezernierte proteine exprimierenden zellen
US20090137416A1 (en) 2001-01-16 2009-05-28 Regeneron Pharmaceuticals, Inc. Isolating Cells Expressing Secreted Proteins
CN100473664C (zh) * 2002-12-20 2009-04-01 拜奥根Idec马萨诸塞公司 多价淋巴毒素β受体激动剂及其治疗用途
TWI328614B (en) 2002-12-23 2010-08-11 Bristol Myers Squibb Co Product quality enhancement in mammalian cell culture processes for protein production
EP1575998A4 (de) 2002-12-23 2007-07-25 Bristol Myers Squibb Co Verfahren zur kultivierung vonsäugetierzellen zur proteinproduktion
WO2005024012A1 (en) * 2003-09-11 2005-03-17 Novozymes A/S Increased expression of a modified polypeptide
WO2005063813A2 (en) * 2003-12-23 2005-07-14 Applied Research Systems Ars Holding N.V. Process for the production of tumor necrosis factor-binding proteins
WO2007115230A2 (en) * 2006-03-30 2007-10-11 University Of Medicine And Dentistry Of New Jersey A strategy for homo- or hetero-dimerization of various proteins in solutions and in cells
NZ576032A (en) 2006-10-12 2012-03-30 Genentech Inc Antibodies to lymphotoxin-alpha
NZ576424A (en) 2006-10-20 2012-09-28 Biogen Idec Inc Treatment of demyelinating disorders with soluble lymphotoxin-beta-receptor
US8338376B2 (en) * 2006-10-20 2012-12-25 Biogen Idec Ma Inc. Compositions comprising variant LT-B-R-IG fusion proteins
CA2680792A1 (en) * 2007-03-15 2008-09-18 Biogen Idec Ma Inc. Treatment of autoimmune disorders
TW200902708A (en) 2007-04-23 2009-01-16 Wyeth Corp Methods of protein production using anti-senescence compounds
JP2011514895A (ja) * 2008-02-29 2011-05-12 バイオジェン・アイデック・エムエイ・インコーポレイテッド 精製免疫グロブリン融合タンパク質およびその精製方法
US9540426B2 (en) 2009-10-06 2017-01-10 Bristol-Myers Squibb Company Mammalian cell culture processes for protein production
LT2563906T (lt) 2010-04-26 2018-02-26 Novartis Ag Cho ląstelių kultivavimo būdas
EP2723759A4 (de) * 2011-06-24 2015-01-28 Reddys Lab Ltd Dr Aufreinigung von chimärem protein
ES2651483T3 (es) 2011-08-17 2018-01-26 Ares Trading S.A. Método para preparar la forma activa de la proteína de fusión TNRF-Fc
EP2906683B1 (de) 2012-10-15 2017-05-31 Bristol-Myers Squibb Company Säugerzellkulturverfahren zur proteinproduktion
TWI864338B (zh) 2012-11-14 2024-12-01 美商再生元醫藥公司 重組細胞表面捕捉蛋白質
AU2016286108B2 (en) 2015-06-30 2021-03-11 Pfizer Inc. BTLA fusion protein agonists and uses thereof
KR101936049B1 (ko) 2015-10-15 2019-01-08 (주)알테오젠 IgG Fc 도메인을 가지는 융합 단백질의 생산방법
CN105400721A (zh) * 2015-12-11 2016-03-16 湖南农业大学 一种快速筛选具有抗菌活性芽孢杆菌的方法

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2906096A (en) 1953-12-14 1959-09-29 Pacific Ind Mfg Co Precision control system for press brakes or the like
WO1991000347A1 (en) 1989-07-04 1991-01-10 Novo Nordisk A/S Method of producing proteins with fviii activity and/or fviii derivatives
US5605690A (en) * 1989-09-05 1997-02-25 Immunex Corporation Methods of lowering active TNF-α levels in mammals using tumor necrosis factor receptor
DK0536299T3 (da) * 1990-06-27 2001-07-09 Univ California Overfladekompleksbundet lymfotolksin
US7030080B2 (en) * 1990-06-27 2006-04-18 Biogen, Inc. Lymphotoxin-β, lymphotoxin-β complexes, pharmaceutical preparations and therapeutic uses thereof
US5670149A (en) * 1990-06-27 1997-09-23 Biogen, Inc. Lymphotoxin-β, Lymphotoxin-β complexes, pharmaceutical preparations and therapeutic uses thereof
ES2139598T3 (es) 1990-07-10 2000-02-16 Medical Res Council Procedimientos para la produccion de miembros de parejas de union especifica.
NZ260103A (en) * 1990-11-30 1996-10-28 Bio Technology General Corp Somatotropin with alterations in the alpha-helix-1 region
US5656272A (en) * 1991-03-18 1997-08-12 New York University Medical Center Methods of treating TNF-α-mediated Crohn's disease using chimeric anti-TNF antibodies
IE922437A1 (en) * 1991-07-25 1993-01-27 Idec Pharma Corp Recombinant antibodies for human therapy
US5447851B1 (en) * 1992-04-02 1999-07-06 Univ Texas System Board Of Dna encoding a chimeric polypeptide comprising the extracellular domain of tnf receptor fused to igg vectors and host cells
WO1993023434A2 (en) * 1992-05-19 1993-11-25 Xoma Corporation Bpi-immunoglobulin fusion proteins
NZ256293A (en) * 1992-09-15 1997-06-24 Immunex Corp Method of treating tumour necrosis factor - mediated inflammation by use of tnf antagonist
WO1994006478A1 (en) 1992-09-22 1994-03-31 Medin Corporation A system for securing medical tools for sterilization
ATE199392T1 (de) 1992-12-04 2001-03-15 Medical Res Council Multivalente und multispezifische bindungsproteine, deren herstellung und verwendung
US5691196A (en) * 1992-12-31 1997-11-25 American Cyanamid Company Recombinant nucleic acid containing a response element
US5429746A (en) * 1994-02-22 1995-07-04 Smith Kline Beecham Corporation Antibody purification
US5856179A (en) 1994-03-10 1999-01-05 Genentech, Inc. Polypeptide production in animal cell culture
US5726039A (en) * 1994-07-21 1998-03-10 Yissum Research Development Co. Of The Hebrew University Of Jerusalem Vectors and transformed host cells for recombinant protein production at reduced temperatures
US5541087A (en) * 1994-09-14 1996-07-30 Fuji Immunopharmaceuticals Corporation Expression and export technology of proteins as immunofusins
US6312691B1 (en) * 1996-01-26 2001-11-06 Jeffrey L. Browning Lymphotoxin-α/β complexes and anti-lympotoxin-β receptor antibodies as anti-tumor agents
US5705364A (en) 1995-06-06 1998-01-06 Genentech, Inc. Mammalian cell culture process
US5721121A (en) * 1995-06-06 1998-02-24 Genentech, Inc. Mammalian cell culture process for producing a tumor necrosis factor receptor immunoglobulin chimeric protein
US5925351A (en) * 1995-07-21 1999-07-20 Biogen, Inc. Soluble lymphotoxin-β receptors and anti-lymphotoxin receptor and ligand antibodies as therapeutic agents for the treatment of immunological disease
US6291207B1 (en) * 1995-07-28 2001-09-18 Northwestern University Herpes virus entry receptor protein
JP4306813B2 (ja) 1995-09-19 2009-08-05 アスビオファーマ株式会社 動物細胞の新規培養方法
WO1997041895A2 (en) * 1996-05-08 1997-11-13 F. Hoffmann-La Roche Ag TREATMENT OF ASTHMA WITH TNFR-Ig
US6040560A (en) * 1996-10-22 2000-03-21 Philip Morris Incorporated Power controller and method of operating an electrical smoking system
US7255854B1 (en) * 1996-10-25 2007-08-14 Biogen, Inc. Use of lymphotoxin-β receptor blocking agents for the treatment of antibody mediated immunological diseases
BR9712670A (pt) * 1996-10-25 1999-10-19 Biogen Inc Receptores para linfotoxina-beta, anticorpos anti-receptor para linfotoxina, e anticorpos antiligante de linfotoxina como agentes terapêuticos para o tratamento de doencas imunológicas
WO1998018824A1 (en) * 1996-10-30 1998-05-07 Human Genome Sciences, Inc. Human tumor necrosis factor receptor-like 2
AU5516898A (en) * 1996-12-12 1998-07-03 Genentech Inc. Hvem polypeptides and uses thereof
US6221608B1 (en) * 1997-01-22 2001-04-24 Ortho Pharmaceutical Corporation Methods for identifying erythropoietin receptor binding protein
US7060667B1 (en) * 1998-01-30 2006-06-13 Biogen Idec Ma, Inc. Treatment of follicular lymphomas using inhibitors of the LT pathway
WO1999053059A1 (en) * 1998-04-16 1999-10-21 Genentech, Inc. Secretion of glycosylated proteins using a tissue plasminogen activator pro-sequence
DE69929198T2 (de) 1998-05-29 2006-08-10 Genentech, Inc., South San Francisco Zellkulturverfahren für die produktion von glycoproteinen
TR200100974T2 (tr) * 1998-10-09 2001-11-21 Biogen, Inc. Virütik kaynaklı sistematik şok ve solunum zorluğunun,lenfotoksin beta yolunu bloke etmek suretiyle geri çevrilmesi
US7294481B1 (en) * 1999-01-05 2007-11-13 Immunex Corporation Method for producing recombinant proteins
US9086881B2 (en) 2012-06-29 2015-07-21 Intel Corporation Mechanism for facilitating write tracking for following data eye movements across changing thermal conditions in memory systems

Also Published As

Publication number Publication date
IL143670A0 (en) 2002-04-21
EP2374872A3 (de) 2011-10-19
US20020039580A1 (en) 2002-04-04
KR20070091227A (ko) 2007-09-07
HK1038244A1 (en) 2002-03-08
JP2014239697A (ja) 2014-12-25
EA200100670A1 (ru) 2001-12-24
NO20012991D0 (no) 2001-06-15
AU777232B2 (en) 2004-10-07
CA2354539A1 (en) 2000-06-22
TR200101703T2 (tr) 2002-05-21
CN1333819A (zh) 2002-01-30
HK1223398A1 (en) 2017-07-28
IS5959A (is) 2001-05-31
US8283138B2 (en) 2012-10-09
JP2010158252A (ja) 2010-07-22
CZ20012156A3 (cs) 2001-09-12
EP2374872A2 (de) 2011-10-12
NZ529276A (en) 2005-03-24
DK2374872T4 (en) 2019-04-23
JP2003517277A (ja) 2003-05-27
EP2374872B2 (de) 2019-02-20
CY1117003T1 (el) 2017-04-05
EP3006563A1 (de) 2016-04-13
WO2000036092A2 (en) 2000-06-22
ES2554482T5 (es) 2019-07-18
US20130196376A1 (en) 2013-08-01
KR100732934B1 (ko) 2007-06-29
NZ549623A (en) 2008-05-30
AU2005200042A1 (en) 2005-02-03
WO2000036092A3 (en) 2000-11-23
PL348816A1 (en) 2002-06-17
BR9916325A (pt) 2001-10-02
US8709759B2 (en) 2014-04-29
IL205698A (en) 2015-11-30
EP1141248A2 (de) 2001-10-10
SI2374872T2 (sl) 2019-05-31
JP5777171B2 (ja) 2015-09-09
EP1141248B1 (de) 2011-12-07
EA005270B1 (ru) 2004-12-30
AU2005200042B2 (en) 2008-05-01
US20100136625A1 (en) 2010-06-03
NO20012991L (no) 2001-08-17
SI2374872T1 (sl) 2016-03-31
CN101289512A (zh) 2008-10-22
EP2374872B1 (de) 2015-11-25
ATE536372T1 (de) 2011-12-15
KR20060084860A (ko) 2006-07-25
JP2013116118A (ja) 2013-06-13
ES2554482T3 (es) 2015-12-21
WO2000036092A9 (en) 2002-08-22
IL229738A0 (en) 2014-01-30
DK1141248T3 (da) 2012-03-12
BR9916325B1 (pt) 2011-06-28
CN100387708C (zh) 2008-05-14
SK8552001A3 (en) 2001-12-03
TR200504220T2 (tr) 2007-04-24
HUP0200064A2 (en) 2002-05-29
NZ538599A (en) 2007-11-30
KR20020013482A (ko) 2002-02-20
JP4878676B2 (ja) 2012-02-15
SG123531A1 (en) 2006-07-26
PT2374872E (pt) 2015-12-09
AU2364400A (en) 2000-07-03
US7585946B2 (en) 2009-09-08
DK2374872T3 (en) 2015-12-14

Similar Documents

Publication Publication Date Title
NO20012991D0 (no) Fremgangsmåte ved höynivå-ekspresjon av aktive chimeriske proteiner av lymfotoksin-<beta>-reseptor-immunoglobulin samtopprenskning derav
DE69528128D1 (de) Rekombinante Chimäre Proteine und Verfahren zur deren Verwendung
DK0627002T3 (da) Kloning og ekspression af humaniserede monoklonale antistoffer mod human interleukin-4
NO994998L (no) Fusjonsproteiner
EE9600015A (et) Meetod ja seade pehmete bioloogiliste kudede omavõnkumise registreerimiseks - müomeeter
DK0921395T3 (da) Assays til måling af proteinfragmenter i biologiske medier
NO20004218D0 (no) Íkning av den sirkulerende halveringstiden til et antistoff- basert fusjonsprotein
KR950700779A (ko) 단백질의 정제방법(Protein purification)
DK0943097T3 (da) Fremgangsmåde til at påvise IgE
DE69703048D1 (de) Glaszusammensetzung, verfahren und verwendung
NO20025354D0 (no) Pattedyr-reseptorproteiner; beslektede reagenser og fremgangsmÕter
DK245284D0 (da) Fremgangsmaade til biologisk afsvovling af kul,samt fremgangsmaade til selektiv fremstilling af mikroorganismer til odoevelse heraf
CY1109093T1 (el) Πρωτεϊνες των υποδοχεων θηλαστικων, σχετικα αντιδραστηρια και σχετικες μεθοδοι
DE69520340D1 (de) Apparat und Methode zur Chipausbeuteermittlung
NO993424L (no) FremgangsmÕte til selektiv nedbrytning av melkeprotein i nærvær av andre melkeproteiner
DE69431638D1 (de) Automatische Fokusausgleicheinstellvorrichtung und Verfahren
ATE414417T1 (de) Translations-kontrollelemente für proteinexpression mit hoher ausbeute in den plastiden von höheren pflanzen und verfahren zu deren verwendung
DE69706920D1 (de) UV-härtbare Zusammensetzung und Verfahren zur, gegebenenfalls bildmässigen, Aushärtung
DK0749481T3 (da) Humaniserede monoklonale antistoffer mod human interleukin-4
DK0977873T3 (da) Fremgangsmåde til spaltning af fusionsproteiner
NO971567D0 (no) Fremgangsmåte for rensing av keratinocyttvekstfaktorer
DK0912107T3 (da) Fremgangsmåde til reducering af nedbrydeligheden af dyrefoderprotein
EP0556320A4 (en) Monoclonal antibodies to hepatitis c virus and method for using same
DE69635297D1 (de) Licht- und wärmeempfindliches Aufzeichnungsmaterial und Aufzeichnungsverfahren, das dieses Material verwendet
EE04007B1 (et) Meetod kristalliliste ainete puhastamiseks

Legal Events

Date Code Title Description
HC1A Change of owner name